Michael O'Riordan is a Senior Journalist for TCTMD, specializing in the field of cardiology and cardiovascular research. With a focus on providing up-to-date and accurate information, Michael's articles cover a wide range of topics including clinical trials, treatment options, and emerging trends in the field of cardiology.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Michael O'Riordan's articles predominantly cite data and cover topics related to cardiovascular disease, medical research, treatment options, and risk factors. He would likely be receptive to pitches offering insights from experts in the healthcare and pharmaceutical industry who can provide informed perspectives on new research findings, treatment developments, or changes in medical guidelines related to cardiovascular diseases.
Given his focus on citing data extensively in his coverage, he may appreciate pitches that offer access to proprietary or exclusive datasets relevant to the topics he covers. Additionally, sources with a deep understanding of scientific methodologies and clinical trial design could capture Michael's interest.
While there is no specified geographic focus for Michael's work, his articles appear internationally focused based on the subjects covered.
This information evolves through artificial intelligence and human feedback. Improve this profile .
One is an siRNA biologic, the other an oral agent, but both lowered Lp(a) levels by 80% or more in ASCVD patients.
By: Michael O'Riordan
The observed changes were favorable, but results may have been affected by better-than-normal care in the control arm.
These data should help reassure those concerned with the risks of educating physicians through live cases at medical meetings.
There was a higher risk of death with the older-generation valves, which investigators attribute to paravalvular leaks.
Investigators saw more deaths in patients with severe TR after repeat mitral valve procedures; what to do about it is unclear.
By: Michael O Riordan
In the CONDUCT-TAVI study, the use of a self-expanding valve was not associated with an increased risk of pacemaker.
An echo analysis highlights changes in the right ventricle that contribute to patient's improved QoL with tricuspid TEER.
By: Michael O Riordan
Choosing between Pascal and MitraClip comes down to patient anatomy, with both devices working well in most cases.
By: Michael O'Riordan
The reason for the disparity is unknown but is not believed to be genetic. Female athletes appear to be at the lowest risk.
The new data may spark fresh debate over alcohol's once-celebrated cardioprotective benefits: not everyone is convinced.
(833) 317-6278 
